Endostar (recombinant human endostatin)

Envafolimab combined with Rh-endostatin demonstrated favorable efficacy and tolerable toxicity in patients with PD-L1-positive, advanced driver-gene negative NSCLC.

While vebreltinib appears clinically advantageous over crizotinib for METex14-mutated NSCLC, the therapeutic benefits did not reach statistical significance in this study. The observed differential response patterns and resistance mechanisms suggest distinct biological behaviors to type Ia and Ib MET TKIs that warrant further investigation. These findings underscore the need for larger prospective studies to validate the potential superiority of vebreltinib and to better characterize the molecular determinants in NSCLC.

P=N/A, N=150, Henan Cancer Hospital; Henan Cancer Hospital

The patient received first-line and maintenance therapy comprising carboplatin/pemetrexed, camrelizumab, and Endostar/bevacizumab...Our findings suggest that the combination of chemotherapy, immunotherapy, and anti-angiogenic agents may represent a viable therapeutic strategy for patients with KRAS G13C/TP53 co-mutated NSCLC. This case report suggests a potentially promising therapeutic strategy to improve long-term survival in this difficult-to-treat patient population.

P=N/A, N=30, Recruiting, Beijing Hospital; Beijing Hospital

This work demonstrated for the first time that Endostar enhanced the antitumor efficacy of Osimertinib, offering a potential therapeutic approach for patients harboring triple mutations.

P3, N=290, Active, not recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Jun 2022 --> Feb 2025

P1/2, N=10, Completed, Shanghai 6th People's Hospital | Recruiting --> Completed | Trial completion date: Oct 2025 --> Jul 2025 | Trial primary completion date: Sep 2025 --> Apr 2025

The incidence of AEs of any level was higher in the E + T group than the T group (53.2% vs. 45.1%, P=0.39). In this real-world study, the combination of recombinant human endostatin and third-generation EGFR-TKIs significantly improved the ORR, PFS, and OS in previously untreated advanced EGFR-mutant NSCLC patients and thus represents a promising treatment option that requires further prospective evaluation.

P2, N=59, Recruiting, Fujian Provincial Hospital; Fujian Provincial Hospital

P2, N=52, Completed, Fudan University | Unknown status --> Completed | N=76 --> 52

The scarcity of approved EGFR-TKIs targeting rare EGFR mutations in NSCLC, coupled with nephrotic syndrome-induced renal impairment, hypoalbuminemia, and massive pleural effusion refractory to conventional management, prompted the development of a personalized multimodal approach.A multimodal therapeutic regimen incorporating albumin-bound paclitaxel, intrathoracic perfusion of Endostar (recombinant human endostatin), and traditional Chinese medicine (TCM) was implemented, achieving effective disease control. Notably, the treatment resulted in significant tumor shrinkage (reduction rate: 48.1% by RECIST 1.1), complete resolution of malignant pleural effusion, and marked improvement in nephrotic syndrome parameters. The synergistic effects of targeted chemotherapy, anti-angiogenic therapy, and TCM-based symptom modulation highlight the potential of integrative approaches in managing advanced malignancies with complex molecular profiles and multisystem complications.